Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients
Background. Medullary thyroid cancer (MTC) is a rare neuroendocrine-derived malignancy. It is represented by sporadic and familiar forms, and both can have RET oncogene mutations. Numerous markers can be used to define MTC; however, none is generally approved for predicting the outcome of sporadic M...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2019/9421079 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554654146232320 |
|---|---|
| author | Raffaele Pezzani Loris Bertazza Elisabetta Cavedon Simona Censi Jacopo Manso Sara Watutantrige-Fernando Gianmaria Pennelli Francesca Galuppini Susi Barollo Caterina Mian |
| author_facet | Raffaele Pezzani Loris Bertazza Elisabetta Cavedon Simona Censi Jacopo Manso Sara Watutantrige-Fernando Gianmaria Pennelli Francesca Galuppini Susi Barollo Caterina Mian |
| author_sort | Raffaele Pezzani |
| collection | DOAJ |
| description | Background. Medullary thyroid cancer (MTC) is a rare neuroendocrine-derived malignancy. It is represented by sporadic and familiar forms, and both can have RET oncogene mutations. Numerous markers can be used to define MTC; however, none is generally approved for predicting the outcome of sporadic MTC. Aim. The aim of this work was to analyze PTTG1/securin and Aurora kinase A expressions in MTC patients, both at the gene and protein levels, and to define their prognostic role in MTC assessing their association with lab and clinical parameters. Patients and Methods. Seventy-one sporadic MTC human samples were analyzed for RET mutations and by qPCR for PTTG1 and AURKA (Aurora kinase A) expression. Ki-67 levels and western blot reactivity for PTTG1 and Aurora kinase A were also determined in a selected cohort of patients. Results. RET somatic mutations were found in 48% of the patients (34/71). PTTG1 expression was statistically different among the groups with or without regional lymph node metastasis (p<0.0001) and advanced stage disease (p<0.01). PTTG1 and AURKA expressions were statistically higher than those of controls (p=0.01 and p<0.002, respectively). PTTG1 expression and Ki-67 levels were statistically different among the groups with remitted or persistent disease (p<0.05 and p<0.01, respectively). We found a significant correlation between the expressions of AURKA and PTTG1 (p<0.0002, r=0.5298) and between the expressions of PTTG1 and Ki-67 (p=0.01). Ki-67 levels were statistically different among the groups with or without metastatic lymph nodes (p=0.01) or distant metastases (p=0.003). Conclusion. The presence of an altered expression of PTTG1 and AURKA is a negative prognostic factor associated with a more aggressive course of disease, such as an advanced stage or disease persistence. It emerges as a cell cycle process mediated by the 2 factors, in addition to the RET pathway, which can be altered in MTC patients. |
| format | Article |
| id | doaj-art-b041cc554e4541f5b0901382bfeb0625 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-b041cc554e4541f5b0901382bfeb06252025-02-03T05:50:52ZengWileyInternational Journal of Endocrinology1687-83371687-83452019-01-01201910.1155/2019/94210799421079Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer PatientsRaffaele Pezzani0Loris Bertazza1Elisabetta Cavedon2Simona Censi3Jacopo Manso4Sara Watutantrige-Fernando5Gianmaria Pennelli6Francesca Galuppini7Susi Barollo8Caterina Mian9Endocrinology Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale 105, Padova 35128, ItalyEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale 105, Padova 35128, ItalyEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale 105, Padova 35128, ItalyEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale 105, Padova 35128, ItalyEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale 105, Padova 35128, ItalyEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale 105, Padova 35128, ItalySurgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padova, Via Gabelli 61, 35121 Padova, ItalySurgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padova, Via Gabelli 61, 35121 Padova, ItalyEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale 105, Padova 35128, ItalyEndocrinology Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale 105, Padova 35128, ItalyBackground. Medullary thyroid cancer (MTC) is a rare neuroendocrine-derived malignancy. It is represented by sporadic and familiar forms, and both can have RET oncogene mutations. Numerous markers can be used to define MTC; however, none is generally approved for predicting the outcome of sporadic MTC. Aim. The aim of this work was to analyze PTTG1/securin and Aurora kinase A expressions in MTC patients, both at the gene and protein levels, and to define their prognostic role in MTC assessing their association with lab and clinical parameters. Patients and Methods. Seventy-one sporadic MTC human samples were analyzed for RET mutations and by qPCR for PTTG1 and AURKA (Aurora kinase A) expression. Ki-67 levels and western blot reactivity for PTTG1 and Aurora kinase A were also determined in a selected cohort of patients. Results. RET somatic mutations were found in 48% of the patients (34/71). PTTG1 expression was statistically different among the groups with or without regional lymph node metastasis (p<0.0001) and advanced stage disease (p<0.01). PTTG1 and AURKA expressions were statistically higher than those of controls (p=0.01 and p<0.002, respectively). PTTG1 expression and Ki-67 levels were statistically different among the groups with remitted or persistent disease (p<0.05 and p<0.01, respectively). We found a significant correlation between the expressions of AURKA and PTTG1 (p<0.0002, r=0.5298) and between the expressions of PTTG1 and Ki-67 (p=0.01). Ki-67 levels were statistically different among the groups with or without metastatic lymph nodes (p=0.01) or distant metastases (p=0.003). Conclusion. The presence of an altered expression of PTTG1 and AURKA is a negative prognostic factor associated with a more aggressive course of disease, such as an advanced stage or disease persistence. It emerges as a cell cycle process mediated by the 2 factors, in addition to the RET pathway, which can be altered in MTC patients.http://dx.doi.org/10.1155/2019/9421079 |
| spellingShingle | Raffaele Pezzani Loris Bertazza Elisabetta Cavedon Simona Censi Jacopo Manso Sara Watutantrige-Fernando Gianmaria Pennelli Francesca Galuppini Susi Barollo Caterina Mian Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients International Journal of Endocrinology |
| title | Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients |
| title_full | Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients |
| title_fullStr | Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients |
| title_full_unstemmed | Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients |
| title_short | Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients |
| title_sort | novel prognostic factors associated with cell cycle control in sporadic medullary thyroid cancer patients |
| url | http://dx.doi.org/10.1155/2019/9421079 |
| work_keys_str_mv | AT raffaelepezzani novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT lorisbertazza novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT elisabettacavedon novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT simonacensi novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT jacopomanso novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT sarawatutantrigefernando novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT gianmariapennelli novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT francescagaluppini novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT susibarollo novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients AT caterinamian novelprognosticfactorsassociatedwithcellcyclecontrolinsporadicmedullarythyroidcancerpatients |